TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Knowledge Translation in Nutrition Through a Healthy Eating Blog: a Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate the effects of an evidence-based healthy eating blog on dietary behaviors of mothers


Options:
A: Arm Label: parent-targeted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multi-component/setting parent-targeted intervention | Arm Label: Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: multi-component/setting parent-targeted intervention; Assigned to Arm(s): parent-targeted intervention
B: Arm Label: Narrative (target); Type: EXPERIMENTAL; Interventions: Behavioral: Narrative | Arm Label: Narrative+ experiential (target); Type: EXPERIMENTAL; Interventions: Behavioral: Narrative, Behavioral: Experiential | Arm Label: Narrative (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Narrative | Arm Label: Narrative+ experiential (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Narrative, Behavioral: Experiential | Intervention Type: BEHAVIORAL; Name: Narrative; Assigned to Arm(s): Narrative (control), Narrative (target), Narrative+ experiential (control), Narrative+ experiential (target) | Intervention Type: BEHAVIORAL; Name: Experiential; Assigned to Arm(s): Narrative+ experiential (control), Narrative+ experiential (target)
C: Arm Label: Standard well child care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food Activity Breast feeding support; Type: EXPERIMENTAL; Interventions: Behavioral: FAB | Arm Label: Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep | Arm Label: FAB + Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: FAB, Behavioral: Sleep | Intervention Type: BEHAVIORAL; Name: FAB; Assigned to Arm(s): FAB + Sleep, Food Activity Breast feeding support | Intervention Type: BEHAVIORAL; Name: Sleep; Assigned to Arm(s): FAB + Sleep, Sleep
D: Arm Label: Healthy eating blog (HEB); Type: EXPERIMENTAL; Interventions: Behavioral: Healthy eating blog | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy eating blog; Assigned to Arm(s): Healthy eating blog (HEB)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Post-transplantation Diabetes Mellitus
Brief Summary: This is a single-center, prospective, controlled, double-blind, randomized study. A total of 50 renal transplant recipients diagnosed with post-transplantation diabetes mellitus (PTDM) will be included more than 1 year after transplantation and randomized 1:1 to empagliflozin (Jardiance®) 10 mg or placebo once daily for 24 weeks. Patients with estimated glomerular filtration rate below 30 mL/min will be excluded. Oral glucose tolerance test, 72h continuous glucose monitoring (iPro™2), measurement of arterial stiffness, body composition (including visceral fat), 24h blood pressure and 24h urinary glucose excretion will be performed at baseline and after 24 weeks in addition to standard safety measurements. Two safety visits will be performed at week 8 and 16. All concomitant medication, diet and exercise will be kept stable during the study period. The objective of the present study is to answer whether empagliflozin safely and effectively improves glucose metabolism together with weight loss in renal transplant recipients with PTDM.


Options:
A: Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Glucagon-like peptide-1 (GLP-1); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Glucagon-like peptide-1 (GLP-1), Other: Hyperglycemic clamp | Arm Label: Isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Isotonic saline, Other: Hyperglycemic clamp | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucagon-like peptide-1 (GLP-1); Assigned to Arm(s): Glucagon-like peptide-1 (GLP-1) | Intervention Type: OTHER; Name: Isotonic saline; Assigned to Arm(s): Isotonic saline | Intervention Type: OTHER; Name: Hyperglycemic clamp; Assigned to Arm(s): Glucagon-like peptide-1 (GLP-1), Isotonic saline
C: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Dapagliflozin 10 mg; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delivery of Self-management Through a Peer-support Telehealth Intervention in Patients With Cardiovascular Disease: The Healing Circles Project
Brief Summary: Heart disease is a leading cause of death and disability in Canada. Providing social and peer supports has been proven to help patients manage their health and stay out of the hospital. The use of telehealth has opened up a wider possibility of patients receiving peer support while staying in their homes and communities. The investigators plan to study a new application for supporting patients through peer support. The application can be accessed by smartphone, tablet and desktop/laptop computer. Over two years, the investigators anticipate that the application (Healing Circles) will improve patient self care and reduce hospitalizations.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Education | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Education; Assigned to Arm(s): Intervention
B: Arm Label: Family-Centered Empowerment Model; Type: EXPERIMENTAL; Interventions: Other: Family-centered empowerment model | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Family-centered empowerment model; Assigned to Arm(s): Family-Centered Empowerment Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Peer-mentoring; Type: EXPERIMENTAL; Interventions: Other: Peer-mentoring | Intervention Type: OTHER; Name: Peer-mentoring; Assigned to Arm(s): Peer-mentoring
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healing Circles; Type: EXPERIMENTAL; Interventions: Behavioral: Healing Circles | Intervention Type: BEHAVIORAL; Name: Healing Circles; Assigned to Arm(s): Healing Circles

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repetitive Transcranial Magnetic Stimulation for Depression After Basal Ganglia Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness of repetitive transcranial magnetic stimulation(rTMS) in treating depression after basal ganglia ischemic stroke and to examine whether such effects are related to restoration of white matter integrity.Sixty-six participants will be recruited from three centers and randomized with a 1:1 ratio to receive active rTMS treatment or sham rTMS treatment in addition to routine supportive treatments.The data of neuropsychological tests and MRI will be collected at 0, 2 and 4 weeks after the commencement of the treatment.


Options:
A: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
B: Arm Label: Sham Stimulation; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Arm Label: Active Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation; Assigned to Arm(s): Active Stimulation, Sham Stimulation
C: Arm Label: TMS; Type: EXPERIMENTAL; Interventions: Device: TMS | Intervention Type: DEVICE; Name: TMS; Assigned to Arm(s): TMS
D: Arm Label: active rTMS treatment; Type: EXPERIMENTAL; Interventions: Device: active rTMS treatment | Arm Label: sham rTMS treatment; Type: SHAM_COMPARATOR; Interventions: Device: sham rTMS treatment | Intervention Type: DEVICE; Name: active rTMS treatment; Assigned to Arm(s): active rTMS treatment | Intervention Type: DEVICE; Name: sham rTMS treatment; Assigned to Arm(s): sham rTMS treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repetitive Transcranial Magnetic Stimulation for Depression After Basal Ganglia Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness of repetitive transcranial magnetic stimulation(rTMS) in treating depression after basal ganglia ischemic stroke and to examine whether such effects are related to restoration of white matter integrity.Sixty-six participants will be recruited from three centers and randomized with a 1:1 ratio to receive active rTMS treatment or sham rTMS treatment in addition to routine supportive treatments.The data of neuropsychological tests and MRI will be collected at 0, 2 and 4 weeks after the commencement of the treatment.


Options:
A: Arm Label: active rTMS treatment; Type: EXPERIMENTAL; Interventions: Device: active rTMS treatment | Arm Label: sham rTMS treatment; Type: SHAM_COMPARATOR; Interventions: Device: sham rTMS treatment | Intervention Type: DEVICE; Name: active rTMS treatment; Assigned to Arm(s): active rTMS treatment | Intervention Type: DEVICE; Name: sham rTMS treatment; Assigned to Arm(s): sham rTMS treatment
B: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
C: N/A
D: Arm Label: Sham Stimulation; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Arm Label: Active Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation; Assigned to Arm(s): Active Stimulation, Sham Stimulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Strategies for Blood Pressure Control in the Setting of Acute Ischemic Stroke to Reduce Cerebral Hemorrhage After Thrombectomy: Systolic Blood Pressure Target of Less Than 130 mmHg vs Less Than 185 mmHg, for 24 Hours Following Reperfusion, in Patients With Cerebral Infarction Due to Occlusion of the Anterior Circulation
Brief Summary: A randomized, multicenter study comparing two strategies: 1 / standard management of systolic blood pressure according to international recommendations (systolic blood pressure \<185 mm Hg) versus 2 / intensive blood pressure management Systolic with a target \<130 mm Hg.


Options:
A: Arm Label: Best medical management.; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Additional intra-arterial treatment.; Type: EXPERIMENTAL; Interventions: Other: Intra-arterial treatment | Intervention Type: OTHER; Name: Intra-arterial treatment; Assigned to Arm(s): Additional intra-arterial treatment.
B: Arm Label: Higher Systolic Blood Pressure (SBP) Target; Type: EXPERIMENTAL; Interventions: Drug: Nicardipine, Drug: Labetalol, Drug: Hydralazine | Arm Label: Lower SBP (<160 mmHg) Target; Type: EXPERIMENTAL; Interventions: Drug: Nicardipine, Drug: Labetalol, Drug: Hydralazine | Arm Label: Lower SBP (<140mmHg) Target; Type: EXPERIMENTAL; Interventions: Drug: Nicardipine, Drug: Labetalol, Drug: Hydralazine | Intervention Type: DRUG; Name: Nicardipine; Assigned to Arm(s): Higher Systolic Blood Pressure (SBP) Target, Lower SBP (<140mmHg) Target, Lower SBP (<160 mmHg) Target | Intervention Type: DRUG; Name: Labetalol; Assigned to Arm(s): Higher Systolic Blood Pressure (SBP) Target, Lower SBP (<140mmHg) Target, Lower SBP (<160 mmHg) Target | Intervention Type: DRUG; Name: Hydralazine; Assigned to Arm(s): Higher Systolic Blood Pressure (SBP) Target, Lower SBP (<140mmHg) Target, Lower SBP (<160 mmHg) Target
C: Arm Label: Intensive blood pressure management; Type: EXPERIMENTAL; Interventions: Other: Systolic blood pressure target < 130 mm Hg | Arm Label: Standard blood pressure management; Type: ACTIVE_COMPARATOR; Interventions: Other: Systolic blood pressure target < 185 mm Hg | Intervention Type: OTHER; Name: Systolic blood pressure target < 130 mm Hg; Assigned to Arm(s): Intensive blood pressure management | Intervention Type: OTHER; Name: Systolic blood pressure target < 185 mm Hg; Assigned to Arm(s): Standard blood pressure management
D: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure
Brief Summary: This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose diuretics is associated with a reduction in cardiovascular mortality in 90 days after randomization and heart failure events in 90 days after discharge than usual care including stepped intravenous diuretics in acutely decompensated chronic heart failure with fluid overload (not fully responsive to diuretic therapy).


Options:
A: Arm Label: Stepped pharmacologic care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Stepped pharmacologic care | Arm Label: Ultrafiltration; Type: EXPERIMENTAL; Interventions: Device: Ultrafiltration | Intervention Type: DRUG; Name: Stepped pharmacologic care; Assigned to Arm(s): Stepped pharmacologic care | Intervention Type: DEVICE; Name: Ultrafiltration; Assigned to Arm(s): Ultrafiltration
B: Arm Label: Infusional drug treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Furosemide or Furosemide and Dopamine | Arm Label: Ultrafiltration; Type: EXPERIMENTAL; Interventions: Device: Ultrafiltration | Intervention Type: DRUG; Name: Furosemide or Furosemide and Dopamine; Assigned to Arm(s): Infusional drug treatment | Intervention Type: DEVICE; Name: Ultrafiltration; Assigned to Arm(s): Ultrafiltration
C: Arm Label: Continuous Furosemide Infusion; Type: N/A; Interventions: Drug: Continuous Furosemide Infusion | Arm Label: Intermittent Furosemide Infusion; Type: N/A; Interventions: Drug: Intermittent Furosemide Infusion | Intervention Type: DRUG; Name: Continuous Furosemide Infusion; Assigned to Arm(s): Continuous Furosemide Infusion | Intervention Type: DRUG; Name: Intermittent Furosemide Infusion; Assigned to Arm(s): Intermittent Furosemide Infusion
D: Arm Label: Ultrafiltration Group; Type: ACTIVE_COMPARATOR; Interventions: Device: CHIARA-System | Arm Label: Control group (Usual care IV diuretics); Type: OTHER; Interventions: Other: Usual care IV diuretics | Intervention Type: DEVICE; Name: CHIARA-System; Assigned to Arm(s): Ultrafiltration Group | Intervention Type: OTHER; Name: Usual care IV diuretics; Assigned to Arm(s): Control group (Usual care IV diuretics)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Closed Versus Open Abdomen in the Surgical Treatment of Severe Secondary Peritonitis: a Randomized Controlled Clinical Trial
Brief Summary: This is a prospective randomized clinical study. The study will comprise the randomized decision to either A) primarily close the fascia after laparotomy for intra-abdominal infection (CLOSED); or B) leave the fascia open after laparotomy and apply a temporary abdominal closure (TAC) device (OPEN) with a vacuum drain.

Although debatable, both procedures (CLOSED or OPEN abdomen) are acceptable based on current suggested standard of care. Thus, high quality data to direct clinical decision making in this highly lethal condition is urgently required.


Options:
A: Arm Label: Open Abdomen Management with ANPPT dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Open Abdomen Management with ANPPT dressing | Arm Label: Closed Abdomen Management; Type: SHAM_COMPARATOR; Interventions: Other: Closed Abdomen Management | Intervention Type: DEVICE; Name: Open Abdomen Management with ANPPT dressing; Assigned to Arm(s): Open Abdomen Management with ANPPT dressing | Intervention Type: OTHER; Name: Closed Abdomen Management; Assigned to Arm(s): Closed Abdomen Management
B: Arm Label: Open Abdomen - Vacuum Pack; Type: EXPERIMENTAL; Interventions: Device: Vacuum Pack | Arm Label: Double Sylo Bag - Mesh Protocol; Type: ACTIVE_COMPARATOR; Interventions: Device: Double Sylo Bag - Mesh Protocol | Intervention Type: DEVICE; Name: Vacuum Pack; Assigned to Arm(s): Open Abdomen - Vacuum Pack | Intervention Type: DEVICE; Name: Double Sylo Bag - Mesh Protocol; Assigned to Arm(s): Double Sylo Bag - Mesh Protocol
C: Arm Label: Open Abdomen patients; Type: N/A; Interventions: Procedure: Open abdomen procedure | Intervention Type: PROCEDURE; Name: Open abdomen procedure; Assigned to Arm(s): Open Abdomen patients
D: Arm Label: "Stampede" VAC; Type: ACTIVE_COMPARATOR; Interventions: Device: "Stampede" VAC | Arm Label: KCI AbThera; Type: EXPERIMENTAL; Interventions: Device: KCI AbThera | Intervention Type: DEVICE; Name: KCI AbThera; Assigned to Arm(s): KCI AbThera | Intervention Type: DEVICE; Name: "Stampede" VAC; Assigned to Arm(s): "Stampede" VAC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Closed-loop Automatic Oxygen Control (CLAC-4) in Preterm Infants: a Randomized Controlled Trial of a Revised Algorithm
Brief Summary: Two-center, randomised controlled, cross-over clinical trial in preterm infants born at gestational age below 34+1/7 weeks receiving supplemental oxygen and respiratory support (Continous positive airway pressure (CPAP) or Non-invasive Ventilation (NIV) or Invasive Ventilation (IV)). Routine manual control (RMC) of the fraction of inspired oxygen (FiO2) will be tested against RMC supported by closed-loop automatic control (CLAC) with "slow"-algorithm and RMC supported by CLAC with "fast"-algorithm.

The primary hypothesis is, that the use of the "faster" algorithm results in more time within arterial oxygen saturation (SpO2) target range compared to RMC only. The a-priori subordinate hypothesis is, that the faster algorithm is equally effective as the slower algorithm to maintain the SpO2 in the target range.


Options:
A: Arm Label: Automatic Oxygen Control; Type: EXPERIMENTAL; Interventions: Device: Automatic Oxygen control | Arm Label: Manual oxygen control; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Oxygen Control | Intervention Type: DEVICE; Name: Automatic Oxygen control; Assigned to Arm(s): Automatic Oxygen Control | Intervention Type: OTHER; Name: Manual Oxygen Control; Assigned to Arm(s): Manual oxygen control
B: Arm Label: CLiO2; Type: EXPERIMENTAL; Interventions: Device: Automated oxygen control by the CLiO2 algorithm | Arm Label: Oxygenie; Type: EXPERIMENTAL; Interventions: Device: Automated oxygen control by the Oxygenie algorithm | Intervention Type: DEVICE; Name: Automated oxygen control by the CLiO2 algorithm; Assigned to Arm(s): CLiO2 | Intervention Type: DEVICE; Name: Automated oxygen control by the Oxygenie algorithm; Assigned to Arm(s): Oxygenie
C: Arm Label: RMC only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CLAC slow; Type: ACTIVE_COMPARATOR; Interventions: Device: Closed-loop automatic oxygen control (CLAC) slow in addition to RMC | Arm Label: CLAC fast; Type: EXPERIMENTAL; Interventions: Device: Closed-loop automatic oxygen control (CLAC) fast in addition to RMC | Intervention Type: DEVICE; Name: Closed-loop automatic oxygen control (CLAC) fast in addition to RMC; Assigned to Arm(s): CLAC fast | Intervention Type: DEVICE; Name: Closed-loop automatic oxygen control (CLAC) slow in addition to RMC; Assigned to Arm(s): CLAC slow
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Titration of oxygen therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Titration of oxygen therapy | Intervention Type: OTHER; Name: Titration of oxygen therapy; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster Randomised Controlled Trial of M-health Enabled, Nurse Care Coordinator Led Intervention to Improve Management of Hypertension in India: m-Power Heart Project
Brief Summary: This study evaluates the effect of a mobile health technology enabled trained nurse led intervention on control of blood pressure among patients with hypertension seeking care in the community health centres in the southern state of Andhra Pradesh, India. half the community health centres will receive the intervention and the other half will receive the routine care.


Options:
A: Arm Label: Intervention phone call; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Phone Call | Arm Label: Control arm - usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention Phone Call; Assigned to Arm(s): Intervention phone call
B: Arm Label: Passive SMS Group; Type: ACTIVE_COMPARATOR; Interventions: Other: SMS text messaging | Arm Label: Active SMS Group; Type: EXPERIMENTAL; Interventions: Other: SMS text messaging | Intervention Type: OTHER; Name: SMS text messaging; Assigned to Arm(s): Active SMS Group, Passive SMS Group
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Telepharmacist intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telepharmacist intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telepharmacist intervention; Assigned to Arm(s): Telepharmacist intervention

Answer: C